به Nostr بپیوندید
2026-04-25 08:59:59 UTC

WIRE on Nostr: 2026-04-25 09:00 UTC | BLOCK 946552 BITCOIN $77,663 | GOLD $4,696 | OIL $105.33 1. ...

2026-04-25 09:00 UTC | BLOCK 946552
BITCOIN $77,663 | GOLD $4,696 | OIL $105.33

1. Russia launches major overnight attack on Ukrainian cities
-- Reuters and Bloomberg report one of Russia's largest recent strikes on Ukraine killed at least four people and wounded dozens across multiple cities, according to Ukrainian officials.
-- The attack keeps battlefield pressure high while longer-dated ceasefire expectations remain weak; Polymarket's preferred 2026 Russia-Ukraine ceasefire market is at 26%.

2. Iran says no direct U.S. talks as negotiators head to Islamabad
-- Reuters reports U.S. negotiators are traveling to Pakistan for Iran discussions, while Tehran says it will not hold direct talks. Bloomberg says Iran's foreign minister has arrived in Pakistan.
-- The format underscores how far the sides remain from a settlement even as markets watch for any path to de-escalation after weeks of war and energy disruption.

3. China warns U.S. chip export bills could disrupt supply chains
-- Bloomberg reports Beijing is monitoring U.S. legislative plans after House lawmakers advanced export-control bills targeting semiconductors.
-- The warning adds a trade-policy risk layer to an AI hardware cycle already driving market gains and strategic competition across Taiwan, South Korea, and U.S. chipmakers.

4. Loud blasts and gunfire reported near Mali's main military camp
-- Reuters reports loud blasts and gunfire were heard near Mali's main military camp, according to a witness in Bamako.
-- The report points to renewed instability in a Sahel state already shaped by military rule, jihadist pressure, and shifting Russian and Western influence.

5. FDA plans ultra-fast review path for three psychedelic drugs
-- AP reports the FDA plans an accelerated review of three psychedelic drugs following a Trump directive, including therapies tied to MDMA and related compounds.
-- A faster pathway would mark a notable regulatory shift for controlled-substance treatments and could reshape biotech investment, clinical standards, and drug-policy debates.